Read on Twitter
Courtesy of @inside-:
Pfizer's trial has nearly 44,000 people enrolled from six different countries. The results, however, come from just 94 infections. The FDA requires a minimum of 164 infections across all volunteers before it can determine vaccine effectiveness.
Pfizer's trial has nearly 44,000 people enrolled from six different countries. The results, however, come from just 94 infections. The FDA requires a minimum of 164 infections across all volunteers before it can determine vaccine effectiveness.
It appears that among participants, only those with symptoms of COVID-19 were tested. Therefore, it is possible that the vaccine masks symptoms, but still spreads the virus.
Pfizer warns that as the sample size increases, the success rate could drastically change. The company also noted that it is nearly unprecedented to release information on such a small sample size.
The FDA requires that all vaccines be tested on 30,000 people and that symptoms are tracked for two months. Studies show that side effects typically do not become present for months after vaccination.
U.S. authorities warn that it is highly unlikely that the drug will be available before the end of 2020.
The length of protection is still completely unknown with the CEO unwilling to speculate.
The length of protection is still completely unknown with the CEO unwilling to speculate.
